Advicenne, a pharmaceutical company focused on rare kidney diseases, announced that Sibnayal®—a fixed combination of potassium citrate and potassium bicarbonate—is officially reimbursed by the French social security system for treating distal Renal Tubular Acidosis (dRTA). The reimbursement decision, published in the Official Journal, sets the price at €213.41 (including tax) for the 24 mEq dose and €71.46 (including tax) for the 8 mEq dose. This approval ends the early access program and allows Sibnayal® to be dispensed directly through retail pharmacies in France.
The company highlighted that the product, developed and manufactured in France, will now be more easily accessible to patients suffering from dRTA. Advicenne’s CEO noted the significance of this reimbursement after several years of negotiations, emphasizing the benefit to French patients who require this treatment.
**Why this matters**
The official reimbursement of Sibnayal® facilitates broader patient access to a specialized treatment for dRTA, a rare kidney disorder. By enabling distribution through retail pharmacies, patients can obtain their medication more conveniently and without the limitations of early access programs. This decision also underscores the support for innovative, locally developed therapies within the French healthcare system.
Source: NewsData